Hydantoin derivative-containing pharmaceutical composition

• US 9,993,462 B2
• Filed: 06/09/2014
• Issued: 06/12/2018
• Est. Priority Date: 06/09/2014
• Status: Active Grant

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Noda, Hiroshi, Kitamura, Hidetomo, Tamura, Tatsuya
• Primary Examiner(s): Puttlitz, Karl J
• Application Number:
  US15/317,221
• Publication Number:
  US 20170112812A1
• Time in Patent Office: 1,464 Days
• Field of Search: None
• CPC Class Codes: A61K 31/435 having six-membered rings with one nitrogen as the only ring hetero atom
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis

Abstract

The present invention provides pharmaceutical compositions for inducing bone and/or cartilage anabolism, which comprises as an active ingredient a compound represented by formula (1) below and a pharmacologically acceptable salt thereof:

wherein R₁, R₂, R₃, and R₄ are as defined in the claims.

Claims

1. A pharmaceutical composition for inducing bone and/or cartilage anabolism, which comprises as an active ingredient a compound represented by general formula (1) below or a pharmacologically acceptable salt thereof:

2. The pharmaceutical composition of claim 1, wherein R1 and R2 of the compound represented by said general formula (1) or a pharmacologically acceptable salt thereof are selected from the combinations below:

1) R1 is a hydrogen atom or a halogen atom, and R2 is a hydrogen atom, a trifluoromethyl group, or a trifluoromethoxy group, provided that R1 and R2 are not both hydrogen atoms);

2) R1 is a trifluoromethyl group or a trifluoromethoxy group, and R2 is a hydrogen atom or a halogen atom;

3) R1 and R2 bond with each other to form a group represented by the formula below;

3. The pharmaceutical composition of claim 1, wherein R1 and R2 of the compound represented by said general formula (1) or a pharmacologically acceptable salt thereof are selected from the combinations below:

1) R1 is a trifuloromethoxy group and R2 is a fluorine atom;

2) R1 is a bromine atom and R2 is a hydrogen atom;

3) R1 is a trifuloromethoxy group and R2 is a fluorine atom;

4) R1 is a fluorine atom and R2 is a trifluoromethoxy group;

5) R1 is a trifluoromethyl group and R2 is a hydrogen atom;

6) R1 is a hydrogen atom and R2 is a trifluoromethoxy group;

7) R1 and R2 bond with each other to form a group represented by the formula below;

4. The pharmaceutical composition of claim 1, wherein R3 and R4 of the compound represented by said general formula (1) or a pharmacologically acceptable salt thereof are methyl groups.

5. The pharmaceutical composition of claim 1, wherein R3 and R4 of the compound represented by said general formula (1) or a pharmacologically acceptable salt thereof, together with a bound carbon atom, form a ring selected from below:

6. The pharmaceutical composition of claim 1, which comprises as an active ingredient a compound or pharmacologically acceptable salt thereof, wherein the compound is selected from the group consisting of:

1-(4-(2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione;

1-(4-(2-((2-(3-bromophenyl)-4-oxo-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione;

1-(4-(2-((2-(4-fluoro-3-(trifluoromethyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione;

1-(4-(2-((2-(3-fluoro-4-(trifluoromethoxy)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione;

1-(4-(2-((2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-4-oxo-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione;

1-(3,5-dimethyl-4-(2-((4-oxo-2-(3-(trifluoromethyl)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione;

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione);

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-1,3-diazaspiro[4.4]nonane-2,4-dione;

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-8-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione;

5-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-2-oxa-5,7-diazaspiro[3.4]octane-6,8-dione; and

4-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione.

7. The pharmaceutical composition of claim 1, wherein the compound is 1-(3,5-dimethyl-4-(2-((4-oxo-2-(3-(trifluoromethyl)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione or a pharmacologically acceptable salt thereof.

8. The pharmaceutical composition of claim 1, wherein the compound is 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione or a pharmacologically acceptable salt thereof.

9. The pharmaceutical composition of claim 1, wherein the compound is 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]deca-1-en-8-yl)sulfonyl)ethyl)phenyl)-1,3-diazaspiro[4.4]nonane-2,4-dione or a pharmacologically acceptable salt thereof.

10. A method for inducing bone and/or cartilage anabolism, which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof in a pharmaceutically effective amount to a patient in need of prevention or treatment of osteoporosis, improvement of decrease of bone mass in periodontal disease, facilitation of recovery from alveolar bone defect after tooth extraction, prevention or treatment of osteoarthritis, facilitation of recovery from articular cartilage deficiency, prevention or treatment of adynamic bone disease, prevention or treatment of achondroplasia, prevention or treatment of hypochondroplasia, prevention or treatment of osteomalacia, or facilitation of recovery from bone fracture.

11. The method of claim 10, wherein the method for inducing bone and/or cartilage anabolism is a method for preventing or treating osteoporosis, a method for improving decrease of bone mass in periodontal disease, a method for facilitating recovery from alveolar bone defect after tooth extraction, a method for preventing or treating osteoarthritis, a method for promoting recovery from articular cartilage deficiency, a method for preventing or treating adynamic bone disease, a method for preventing or treating achondroplasia, a method for preventing or treating hypochondroplasia, a method for preventing or treating osteomalacia, or a method for facilitating recovery from bone fracture.